Marshall Wace Asia Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Albemarle
ALB
|
+$141M |
| 2 |
Pinduoduo
PDD
|
+$96.6M |
| 3 |
Medtronic
MDT
|
+$95.9M |
| 4 |
Darling Ingredients
DAR
|
+$69.1M |
| 5 |
Boston Scientific
BSX
|
+$40.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Morgan Stanley
MS
|
+$208M |
| 2 |
Norfolk Southern
NSC
|
+$129M |
| 3 |
Illumina
ILMN
|
+$94.8M |
| 4 |
Otis Worldwide
OTIS
|
+$75.7M |
| 5 |
TransUnion
TRU
|
+$72.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 46.24% |
| 2 | Consumer Discretionary | 11.22% |
| 3 | Technology | 10.94% |
| 4 | Industrials | 8.77% |
| 5 | Healthcare | 7.43% |
No holdings matched the selected filter criteria.
Similar funds
Marshall Wace Asia's Q3 2021 Portfolio in Review
As of Q3 2021, Marshall Wace Asia held 187 positions worth $4.23B, down 11% from $4.73B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Marshall Wace Asia withdrew a net $480M in Q3 2021, closing 58 positions and reducing 30 holdings. Its most notable exit was Morgan Stanley, an estimated $208M position sold in full.
By sector, the portfolio is most concentrated in Financials at 46% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Marshall Wace Asia opened a new position in Albemarle worth $145M.
- Marshall Wace Asia's largest Q3 2021 buy was Albemarle: 662,091 shares worth $145M.
- Marshall Wace Asia added most to Pinduoduo in Q3 2021, an estimated $96.6M increase.
- Marshall Wace Asia's biggest Q3 2021 reduction was Otis Worldwide, cutting an estimated $75.7M.
- Marshall Wace Asia fully exited Morgan Stanley in Q3 2021, selling an estimated $208M.
- Marshall Wace Asia's ten largest holdings make up 33% of its $4.23B portfolio in Q3 2021.
- Marshall Wace Asia opened 50 new positions and closed 58 in Q3 2021.
- Marshall Wace Asia's portfolio value fell 11% quarter-over-quarter to $4.23B.
Based on Marshall Wace Asia's 13F filing for Q3 2021, filed 15 Nov 2021.